Navigation Links
Protox Announces Publication in Journal of the National Cancer,Institute Supporting PRX302 as Treatment for Prostatic Diseases

Additional data to be published in an upcoming issue of Anti-Cancer Drugs

VANCOUVER, March 20 /CNW/ - Protox(TM) Therapeutics Inc. (TSX-V:PRX) today announced that two peer-reviewed publications will feature Protox's PRX 302. The Journal of the National Cancer Institute ("JNCI") has published the work conducted by Dr. Sam Denmeade and his team at Johns Hopkins University in collaboration with Protox scientists. The paper describes the Company's compound, PRX302, which is a prostate specific antigen (PSA) activated pro-drug being developed for the treatment of prostate cancer and BPH.

"Having results of our PRX302 research program published in a prestigious journal such as JNCI is a testament to the importance of advancing PRX302 for prostate cancer and BPH," stated Dr. Fahar Merchant, President and CEO of Protox. "The published results are consistent with the encouraging interim data from the ongoing Phase I prostate cancer trial reported earlier this year and supports the planned Phase I BPH clinical trial which we expect to commence in Q2 of 2007."

The major advantage of using PRX302 as a therapeutic agent for prostatic diseases is that it involves direct injection into the target tissue and selective activation by PSA produced only by the target tissue. The paper, entitled "A prostate-specific antigen-activated channel-forming toxin as therapy for prostatic disease" (JNCI, Vol.99, Issue 5 pp, 376-385) found that: PRX302 direct injection into the prostate did not cause any attributable accumulation of PRX302 outside of the prostate gland; is not toxic to adjacent non-PSA producing organs and tissues; and PRX302 has a selective mechanism of action and favourable safety profile.

A second paper entitled, "Recombinant prostate-specific antigen proaerolysin shows selective protease sensitivity and cell cytotoxicity" is to appear in the upcoming issue of Anti-Cancer Drugs (ACD). The journal will publish the work cond ucted by Dr Arthur Frankel and his team at the Cancer Research Institute of Scott and White Memorial Hospital in collaboration with scientists at Protox and Johns Hopkins University. Key findings include: human prostate cancer cells are significantly more sensitive to PRX302 in the presence of active PSA; PRX302 was totally resistant to thrombin, matrix metalloprotease 7 (MMP-7), human kallikrein 1 (hk1) and human kallikrein 2 (hk2) activation; and among the normal cells tested, the PSA-producing prostate epithelial cells were the only normal cells that were highly sensitive to PRX302.

Both publications demonstrated that the PSA-activated strategy for PRX302 has a number of inherent advantages as a therapeutic strategy for locally recurrent prostate cancer and BPH.

About Protox

Protox Therapeutics is a leader in advancing novel, targeted protein toxin therapeutics for treatment of cancer and other proliferative diseases. The company is actively developing two distinct but complementary platforms, INxin(TM) and PORxin, and currently has three clinical programs in
development. A Phase IIa clinical trial into the use of PRX321 (INxin) for the treatment of primary brain cancer has been completed and the drug has received Fast Track Designation and Orphan Drug Status from the US FDA. In addition, a Phase I trial has been completed for PRX321 to treat patients with renal cell carcinoma and non-small cell lung cancer. Patient enrolment is underway for a Phase I clinical study into the use of PRX302 (PORxin) to treat localized prostate cancer. PRX302 has also been approved by Health Canada to commence a Phase I clinical study for the treatment of benign prostatic hyperplasia.

NO REGULATORY AUTHORITY HAS APPROVED OR DISAPPROVED THE CONTENT OF THIS RELEASE. THE TSX VENTURE EXCHANGE DOES NOT ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Certain st atements included in this press release may be considered forward-looking. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on Protox' current beliefs as well as assumptions made by and information currently available to Protox and relate to, among other things, anticipated financial performance, business prospects, strategies, regulatory developments, market acceptance and future commitments. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by Protox in its public securities filings; actual events may differ materially from current expectations. Protox disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

-30-

/For further information: James Beesley, Director, Investor Relations,
Protox Therapeutics, (604) 688-0199, jbeesley@protoxtherapeutics.com; Michael
Moore, Investor Relations, Equicom Group, (416) 815-0700 x 241,
mmoore@equicomgroup.com/



'"/>




Related medicine technology :

1. Protox Announces Positive Clinical Data from Prostate Cancer Study
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... , April 28, 2016 ... George Phillips und Stephen ...    ArisGlobal®, ein führender Anbieter ... gab heute bekannt, dass neue Führungskräfte zum ... gestoßen sind, die vielfältige Erfahrungen mitbringen.  Dies ...
(Date:4/28/2016)... April 28, 2016 Oramed Pharmaceuticals Inc. ... pharmaceutical company focused on the development of oral drug delivery ... upcoming PIONEERS 2016 conference, presented by Joseph Gunnar ... New York . Nadav Kidron , ... conference. Presentation Details:   PIONEERS ...
(Date:4/27/2016)... 27, 2016  Hologic, Inc. (Nasdaq: ... for the fiscal second quarter ended March 26, ... $0.24 increased 41.2%, and non-GAAP diluted EPS of ... 5.8% on a reported basis, and 6.3% on ... posted another good quarter, highlighted by 14.6% growth ...
Breaking Medicine Technology:
(Date:5/2/2016)... ... ... The 2016 World Ultimate & Guts Championship (WUGC) Mixed roster was announced in February and ... WUGC is being held in London, England this year from June 18-25. At the last ... gold in the women’s masters division, and a silver in the women’s division, so Mazur ...
(Date:5/2/2016)... ... May 02, 2016 , ... ... will be held at the Bellagio Hotel in Las Vegas, NV from October ... (NASW) will be co-hosting the event. , This year’s conference will offer ...
(Date:5/2/2016)... , ... May 02, 2016 , ... Dr. Jonathan Kulbersh of Carolina Facial Plastics isn’t ... number five on the list of “ 5 US Cities with the Highest Plastic Rates ... Angeles, and Miami. The results were calculated using a survey by RealSelf ...
(Date:5/2/2016)... Ocean City, MD (PRWEB) , ... May 02, 2016 , ... ... high quality SUP boards at affordable prices announced today the outcome of their partnership ... what has been termed the “Roots Yoga Board.” , SUP yoga has seen a ...
(Date:5/2/2016)... ... May 02, 2016 , ... In response to recent growth and ... Low Vision and Blindness (NELV&B) , announces the opening of a new low vision ... with vision impairments to get assessments, hands-on experience and training with low vision and ...
Breaking Medicine News(10 mins):